Hormone and immune patterns linked in older women’s breast tumors
An observational analysis of 115 patients and 89 donors without breast cancer linked older age to hormone and immune patterns around estrogen-sensitive tumors.
Our read
Mechanisms- Studied:
- Cross-sectional study of patients with ER⁺/HER2⁻ breast cancer
- What changed:
- Tumors with higher estrogen receptor levels had more immune-suppressing macrophages
- The catch:
- Tumors could raise circulating estrogen levels, rather than elevated estrogen preceding tumor formation
Editor of record: Boris Djordjevic · AgingResearch.News
Samples from 115 patients with early-stage, estrogen-sensitive breast cancer and 89 donors without breast cancer were compared in an observational analysis across ages 35–45, 55–69 and 70 or older. The tumors lacked excess HER2, a growth-signaling protein.
Older patients’ blood estrogen was predominantly estrone. Their tumors had more HSD17B7, an enzyme that converts estrone to estradiol, another estrogen, consistent with enhanced local conversion. Older patients’ tumors also had more inflammatory signals associated with immune-suppressing features in macrophages, a type of immune cell. In organoids, three-dimensional tumor cultures from older women, inhibiting HSD17B7 reduced estrogen conversion and gene activity associated with cell multiplication. In lab-grown human macrophages, targeting both estrogen signaling and inflammatory-signal pathways reduced the shift toward immune-suppressing features.
Why it matters
Estrogen-sensitive breast cancer is an age-related disease. The authors’ model offers a way to investigate how hormonal changes and chronic inflammation might shape its biology in older women.
Caveats
Patient samples collected at surgery could not reveal whether the hormone and immune patterns preceded the tumors. The patient cohort excluded perimenopausal women; drug effects were tested in tumor cultures and immune cells, not patients.
The paper
UPMC Health System; University of Pittsburgh
Nature Aging, Jul 27, 2026, Open access

Comments
Be the first to comment.